Angeloylgomisin HCAS# 66056-22-2 |
- Tigloylgomisin H
Catalog No.:BCN6927
CAS No.:66069-55-4
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 66056-22-2 | SDF | Download SDF |
PubChem ID | 26204131 | Appearance | Powder |
Formula | C28H36O8 | M.Wt | 500.58 |
Type of Compound | Lignans | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | [(9S,10S)-10-hydroxy-4,5,14,15,16-pentamethoxy-9,10-dimethyl-3-tricyclo[10.4.0.02,7]hexadeca-1(16),2,4,6,12,14-hexaenyl] (Z)-2-methylbut-2-enoate | ||
SMILES | CC=C(C)C(=O)OC1=C2C(=CC(=C1OC)OC)CC(C(CC3=CC(=C(C(=C32)OC)OC)OC)(C)O)C | ||
Standard InChIKey | ZSAUXCVJDYCLRS-XSIRQHFTSA-N | ||
Standard InChI | InChI=1S/C28H36O8/c1-10-15(2)27(29)36-26-21-17(12-19(31-5)24(26)34-8)11-16(3)28(4,30)14-18-13-20(32-6)23(33-7)25(35-9)22(18)21/h10,12-13,16,30H,11,14H2,1-9H3/b15-10-/t16-,28-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Angeloylgomisin H shows moderate cytotoxic activities with IC50 values ranging from 100 to 200 ug/mL against MCF7, HEK293 and CAL27 cell lines. 2. Angeloylgomisin H may present significant myocardial protective activity. |
Angeloylgomisin H Dilution Calculator
Angeloylgomisin H Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.9977 mL | 9.9884 mL | 19.9768 mL | 39.9537 mL | 49.9421 mL |
5 mM | 0.3995 mL | 1.9977 mL | 3.9954 mL | 7.9907 mL | 9.9884 mL |
10 mM | 0.1998 mL | 0.9988 mL | 1.9977 mL | 3.9954 mL | 4.9942 mL |
50 mM | 0.04 mL | 0.1998 mL | 0.3995 mL | 0.7991 mL | 0.9988 mL |
100 mM | 0.02 mL | 0.0999 mL | 0.1998 mL | 0.3995 mL | 0.4994 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Gomisin H
Catalog No.:BCN3902
CAS No.:66056-20-0
- Licoisoflavone A
Catalog No.:BCN2929
CAS No.:66056-19-7
- Glycyrin
Catalog No.:BCN7681
CAS No.:66056-18-6
- H-D-Arg(NO2)-OH
Catalog No.:BCC2871
CAS No.:66036-77-9
- (5Z)-7-Oxozeaenol
Catalog No.:BCC7724
CAS No.:66018-38-0
- 6-Demethoxytangeretin
Catalog No.:BCN3844
CAS No.:6601-66-7
- Cirsimaritin
Catalog No.:BCN4206
CAS No.:6601-62-3
- H-Nva-OH
Catalog No.:BCC2643
CAS No.:6600-40-4
- Psoralen
Catalog No.:BCN4219
CAS No.:66-97-7
- D-Glucosamine hydrochloride
Catalog No.:BCN5982
CAS No.:66-84-2
- Cycloheximide
Catalog No.:BCC3653
CAS No.:66-81-9
- Dicoumarol
Catalog No.:BCC9225
CAS No.:66-76-2
- Benzoylgomisin H
Catalog No.:BCN7242
CAS No.:66056-23-3
- Licoisoflavone B
Catalog No.:BCN6695
CAS No.:66056-30-2
- Licoisoflavanone
Catalog No.:BCN6856
CAS No.:66067-26-3
- Tigloylgomisin H
Catalog No.:BCN6927
CAS No.:66069-55-4
- GW 542573X
Catalog No.:BCC7914
CAS No.:660846-41-3
- Nimodipine
Catalog No.:BCC3823
CAS No.:66085-59-4
- GW843682X
Catalog No.:BCC1614
CAS No.:660868-91-7
- Docosanol (Abreua)
Catalog No.:BCC3769
CAS No.:661-19-8
- Glochidone
Catalog No.:BCN4207
CAS No.:6610-55-5
- Glochidiol
Catalog No.:BCN4208
CAS No.:6610-56-6
- Pergolide mesylate
Catalog No.:BCC4464
CAS No.:66104-23-2
- 14,17-Epidioxy-28-nor-15-taraxerene-2,3-diol
Catalog No.:BCN1386
CAS No.:66107-60-6
Cytotoxic ethnic Yao medicine Baizuan, leaves of Schisandra viridis A. C. Smith.[Pubmed:27620660]
J Ethnopharmacol. 2016 Dec 24;194:146-152.
ETHNOPHARMACOLOGICAL RELEVANCE: The ethnic Chinese Yao medicine Baizuan, which are the leaves of Schisandra viridis A. C. Smith, is traditionally used, in combination with other herbs, to soften hard lumps and dispel nodes in the treatment of cancer, however, this property has not been well studied with a clear indication of the active principles. AIM OF THE STUDY: The experiments were carried out to investigate the cytotoxic activity of the extracts and to identify the active principles from the extract, which could support the traditional application of treating cancer. MATERIALS AND METHODS: Dried and ground plant material was extracted with water and ethanol and further purified by HPLC. The cytotoxicity of the extracts, fractions and pure compounds were evaluated for their abilities to inhibit the proliferation of breast cancer cells MCF7 and tongue cancer cells CAL27. The cytotoxicity of the pure compounds were also tested against Human Embryonic Kidney cell line HEK293. RESULTS: Both aqueous and ethanol extracts showed activities against MCF7 and CAL27 cancer cells. Bioassay-guided fractionation and purification of the extracts resulted in six active principles, including five dibenzocyclooctene lignans namely gomisin H (1), schisandrin (2), Angeloylgomisin H (3), (+)-gomisin M2 (4) and (-)-rubschisandrin (5), and one triterpenoid, schisanol (6). Compounds 1-3 showed moderate cytotoxic activities with IC50 values ranging from 100 to 200microg/mL against MCF7 and CAL27 cell lines. Dioxane containing lignans 4-5 and triterpenoid 6 were 10 times more active with IC50 values of 14.5, 13.4, 10.6microg/mL against MCF7, and 21.2, 17.9, 11.7microg/mL against CAL27, respectively. Compounds 1-6 also showed cytotoxicity against HEK293 with IC50 values ranging from 10 to 150microg/mL, respectively. CONCLUSIONS: The traditional extraction protocol using boiled water afforded three moderately active lignans 1-3. Ethanol extraction, which is widely used in the preparation of herbal remedies in China, yielded three additional active compounds 4-5 with more potent activities. These results provided a rationale for the traditional application of the ethnic Yao medicine Baizuan in the treatment of cancer.
[Screening of active compounds with myocardial protective effects from Tongmai Yangxin pill].[Pubmed:26038132]
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2015 Mar;44(2):145-53.
OBJECTIVE: Based on cell model and HPLC-MS technology, to screen myocardial protection active compounds from traditional patent medicine Tongmai Yangxin pill (TMYXP). METHODS: Fractions of TMYXP were prepared by high performance liquid preparation technology. The cardioprotective effects of prepared fractions were tested on H2O2 oxidation-damaged H9c2 myocardiocytes. The active components were analyzed by high performance liquid chromatography (HPLC) coupled with high resolution mass spectrometry. The possible active compounds were putatively identified by comparison of their MS ions and molecular weight with literatures. RESULTS: Ten TMYXP components presented significant myocardial protective activities, 5 of which were investigated and presented good dose-effect relationships. Their median effective concentrations (EC50) were respectively 11.66, 17.44, 13.10, 7.332, 15.15 mug/mL. Totally, 11 potential active compounds were analyzed and identified, including Glycyrrhizic acid, Glycycoumarin, Licoisoflavone, Ophiopogonin D', Licoricon, Gancaonin L, Neoglycyrol, Emodin, Angeloylgomisin H, Angeloylgomisin Q and Glyasperin A. CONCLUSION: The myocardial protection active compounds of TMYXP were screened successfully.